<?xml version='1.0' encoding='utf-8'?>
<document id="28345306"><sentence text="The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly."><entity charOffset="113-123" id="DDI-PubMed.28345306.s1.e0" text="metoprolol" /><entity charOffset="128-138" id="DDI-PubMed.28345306.s1.e1" text="paroxetine" /><entity charOffset="142-152" id="DDI-PubMed.28345306.s1.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s1.e0" e2="DDI-PubMed.28345306.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s1.e0" e2="DDI-PubMed.28345306.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s1.e0" e2="DDI-PubMed.28345306.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s1.e1" e2="DDI-PubMed.28345306.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s1.e1" e2="DDI-PubMed.28345306.s1.e2" /></sentence><sentence text="Metoprolol and paroxetine/fluoxetine are inevitably co-prescribed because cardiovascular disorders and depression often coexist in the elderly"><entity charOffset="0-10" id="DDI-PubMed.28345306.s2.e0" text="Metoprolol" /><entity charOffset="15-25" id="DDI-PubMed.28345306.s2.e1" text="paroxetine" /><entity charOffset="26-36" id="DDI-PubMed.28345306.s2.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s2.e0" e2="DDI-PubMed.28345306.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s2.e0" e2="DDI-PubMed.28345306.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s2.e0" e2="DDI-PubMed.28345306.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s2.e1" e2="DDI-PubMed.28345306.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s2.e1" e2="DDI-PubMed.28345306.s2.e2" /></sentence><sentence text=" This leads to CYP2D6-mediated drug-drug interactions (DDI)" /><sentence text=" Because systematic evaluations are lacking, we assessed the burden of metoprolol-paroxetine/fluoxetine interaction in the elderly and how these interactions are managed in Dutch community pharmacies"><entity charOffset="71-81" id="DDI-PubMed.28345306.s4.e0" text="metoprolol" /><entity charOffset="82-92" id="DDI-PubMed.28345306.s4.e1" text="paroxetine" /><entity charOffset="93-103" id="DDI-PubMed.28345306.s4.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s4.e0" e2="DDI-PubMed.28345306.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s4.e0" e2="DDI-PubMed.28345306.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s4.e0" e2="DDI-PubMed.28345306.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s4.e1" e2="DDI-PubMed.28345306.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s4.e1" e2="DDI-PubMed.28345306.s4.e2" /></sentence><sentence text="" /><sentence text="Dispensing data were collected from the University of Groningen pharmacy database (IADB" /><sentence text="nl, 1999-2014) for elderly patients (≥60 years) starting beta-blockers and/or antidepressants" /><sentence text=" Based on the two main DDI alert systems (G-Standard and Pharmabase), incidences were divided between signalled (metoprolol-fluoxetine/paroxetine) and not-signalled (metoprolol-alternative antidepressants and alternative beta-blockers-paroxetine/fluoxetine) combinations"><entity charOffset="113-123" id="DDI-PubMed.28345306.s8.e0" text="metoprolol" /><entity charOffset="124-134" id="DDI-PubMed.28345306.s8.e1" text="fluoxetine" /><entity charOffset="135-145" id="DDI-PubMed.28345306.s8.e2" text="paroxetine" /><entity charOffset="166-176" id="DDI-PubMed.28345306.s8.e3" text="metoprolol" /><entity charOffset="235-245" id="DDI-PubMed.28345306.s8.e4" text="paroxetine" /><entity charOffset="246-256" id="DDI-PubMed.28345306.s8.e5" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e0" e2="DDI-PubMed.28345306.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e0" e2="DDI-PubMed.28345306.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e0" e2="DDI-PubMed.28345306.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e0" e2="DDI-PubMed.28345306.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e0" e2="DDI-PubMed.28345306.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e0" e2="DDI-PubMed.28345306.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e1" e2="DDI-PubMed.28345306.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e1" e2="DDI-PubMed.28345306.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e1" e2="DDI-PubMed.28345306.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e1" e2="DDI-PubMed.28345306.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e1" e2="DDI-PubMed.28345306.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e2" e2="DDI-PubMed.28345306.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e2" e2="DDI-PubMed.28345306.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e2" e2="DDI-PubMed.28345306.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e2" e2="DDI-PubMed.28345306.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e3" e2="DDI-PubMed.28345306.s8.e3" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e3" e2="DDI-PubMed.28345306.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e3" e2="DDI-PubMed.28345306.s8.e5" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e4" e2="DDI-PubMed.28345306.s8.e4" /><pair ddi="false" e1="DDI-PubMed.28345306.s8.e4" e2="DDI-PubMed.28345306.s8.e5" /></sentence><sentence text=" Incident users were defined as patients starting at least one signalled or a non-signalled combination" /><sentence text=" G-Standard signalled throughout the study period, whereas Pharmabase stopped after 2005" /><sentence text="" /><sentence text="A total of 1763 patients had 2039 metoprolol-paroxetine/fluoxetine co-prescriptions, despite DDI alert systems, and about 57"><entity charOffset="34-44" id="DDI-PubMed.28345306.s12.e0" text="metoprolol" /><entity charOffset="45-55" id="DDI-PubMed.28345306.s12.e1" text="paroxetine" /><entity charOffset="56-66" id="DDI-PubMed.28345306.s12.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s12.e0" e2="DDI-PubMed.28345306.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s12.e0" e2="DDI-PubMed.28345306.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s12.e0" e2="DDI-PubMed.28345306.s12.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s12.e1" e2="DDI-PubMed.28345306.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s12.e1" e2="DDI-PubMed.28345306.s12.e2" /></sentence><sentence text="3% were signalled" /><sentence text=" The number of metoprolol-alternative antidepressant combinations (incidences = 3150) was higher than alternative beta-blocker-paroxetine/fluoxetine combinations (incidences = 1872)"><entity charOffset="15-25" id="DDI-PubMed.28345306.s14.e0" text="metoprolol" /><entity charOffset="127-137" id="DDI-PubMed.28345306.s14.e1" text="paroxetine" /><entity charOffset="138-148" id="DDI-PubMed.28345306.s14.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s14.e0" e2="DDI-PubMed.28345306.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s14.e0" e2="DDI-PubMed.28345306.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s14.e0" e2="DDI-PubMed.28345306.s14.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s14.e1" e2="DDI-PubMed.28345306.s14.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s14.e1" e2="DDI-PubMed.28345306.s14.e2" /></sentence><sentence text=" Metoprolol users are more likely to be co-medicated with an alternative antidepressant (incidences = 2320) than paroxetine/fluoxetine users (incidences = 1232) are"><entity charOffset="1-11" id="DDI-PubMed.28345306.s15.e0" text="Metoprolol" /><entity charOffset="113-123" id="DDI-PubMed.28345306.s15.e1" text="paroxetine" /><entity charOffset="124-134" id="DDI-PubMed.28345306.s15.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s15.e0" e2="DDI-PubMed.28345306.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s15.e0" e2="DDI-PubMed.28345306.s15.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s15.e0" e2="DDI-PubMed.28345306.s15.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s15.e1" e2="DDI-PubMed.28345306.s15.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s15.e1" e2="DDI-PubMed.28345306.s15.e2" /></sentence><sentence text=" The number of paroxetine/fluoxetine users co-prescribed with alternative beta-blockers was comparable to those co-medicated with metoprolol (about 50%)"><entity charOffset="15-25" id="DDI-PubMed.28345306.s16.e0" text="paroxetine" /><entity charOffset="26-36" id="DDI-PubMed.28345306.s16.e1" text="fluoxetine" /><entity charOffset="130-140" id="DDI-PubMed.28345306.s16.e2" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.28345306.s16.e0" e2="DDI-PubMed.28345306.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s16.e0" e2="DDI-PubMed.28345306.s16.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s16.e0" e2="DDI-PubMed.28345306.s16.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s16.e1" e2="DDI-PubMed.28345306.s16.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s16.e1" e2="DDI-PubMed.28345306.s16.e2" /></sentence><sentence text=" Less than 5% of patients received a substitute therapy after using metoprolol-paroxetine/fluoxetine"><entity charOffset="68-78" id="DDI-PubMed.28345306.s17.e0" text="metoprolol" /><entity charOffset="79-89" id="DDI-PubMed.28345306.s17.e1" text="paroxetine" /><entity charOffset="90-100" id="DDI-PubMed.28345306.s17.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s17.e0" e2="DDI-PubMed.28345306.s17.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s17.e0" e2="DDI-PubMed.28345306.s17.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s17.e0" e2="DDI-PubMed.28345306.s17.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s17.e1" e2="DDI-PubMed.28345306.s17.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s17.e1" e2="DDI-PubMed.28345306.s17.e2" /></sentence><sentence text=" Most of the metoprolol users (90%) received a low dose (mean DDD = 0"><entity charOffset="13-23" id="DDI-PubMed.28345306.s18.e0" text="metoprolol" /></sentence><sentence text="47) regardless whether they were prescribed paroxetine/fluoxetine"><entity charOffset="44-54" id="DDI-PubMed.28345306.s19.e0" text="paroxetine" /><entity charOffset="55-65" id="DDI-PubMed.28345306.s19.e1" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s19.e0" e2="DDI-PubMed.28345306.s19.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s19.e0" e2="DDI-PubMed.28345306.s19.e1" /></sentence><sentence text="" /><sentence text="Despite the signalling software, metoprolol-paroxetine/fluoxetine combinations are still observed in the elderly population"><entity charOffset="33-43" id="DDI-PubMed.28345306.s21.e0" text="metoprolol" /><entity charOffset="44-54" id="DDI-PubMed.28345306.s21.e1" text="paroxetine" /><entity charOffset="55-65" id="DDI-PubMed.28345306.s21.e2" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.28345306.s21.e0" e2="DDI-PubMed.28345306.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28345306.s21.e0" e2="DDI-PubMed.28345306.s21.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s21.e0" e2="DDI-PubMed.28345306.s21.e2" /><pair ddi="false" e1="DDI-PubMed.28345306.s21.e1" e2="DDI-PubMed.28345306.s21.e1" /><pair ddi="false" e1="DDI-PubMed.28345306.s21.e1" e2="DDI-PubMed.28345306.s21.e2" /></sentence><sentence text=" The clinical impact of these interactions needs further investigation" /><sentence text=" Copyright © 2017 John Wiley &amp; Sons, Ltd" /><sentence text="" /></document>